OmniAb® provides access to diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
OmniAb has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2025.
OmniAb is headquartered in Emeryville, United States.
OmniAb® provides access to diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
OmniAb is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OmniAb — Funding & Investors." VCBacked, August 25, 2025, https://www.vcbacked.co/company/omniab. Accessed August 14, 2026.
VCBacked. (2025). OmniAb — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/omniab
{{cite web |title=OmniAb — Funding & Investors |url=https://www.vcbacked.co/company/omniab |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated